Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis
Journal of Bone and Mineral Metabolism · 2023
DOI: 10.1007/s00774-023-01412-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Mineral Metabolism, 2023. Verfasst von Gosset Anna und 4 weiteren Autor:innen. Beteiligte Einrichtung: Menopause Center, Paule de Viguier Hospital, 330 Avenue de Grande-Bretagne, TSA 70034, Toulouse Cedex 9, 31059, Toulouse, France. gosset.a@chu-toulou…. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: To investigate the factors associated with changes in vertebral bone mineral density during teriparatide treatment. MATERIALS AND METHODS: Single centre, longitudinal study involving 145 osteoporotic postmenopausal women treated with teriparatide. Clinical evaluation, bone mineral density (BMD) measurements assessment and laboratory analyses were performed at baseline then after 12 and 18 months of treatment. Bone non-response to treatment was defined as no significant increase in BMD at 18 months as compared to baseline. RESULTS: Of the 145 women initially included, 109 completed the 18-month course of the treatment. 75% of them had a history of prior osteoporotic treatment. Baseline mean age was 60 ± 8 years. Mean baseline vertebral T-score was - 3.7 ± 0.7 and 83 (76%) women had suffered at least one vertebral fracture. At the end of treatment, 18 women (17%) were classified as non-responders. In the responder group (n = 91), vertebral BMD increased by 0.091 ± 0.04 g/cm2 (12.2 ± 5.3%). Clinical characteristics, baseline BMDs and the percentage of women previously treated with bisphosphonates as well as the duration of prior treatment did not significantly differ between the two groups of responders and non-responders. At baseline, non-responders had significant mean lower C-terminal fragment of type 1 collagen (CTX) values than responders (p < 0.01). Only baseline CTX values (r = 0.30 p < 0.01) were independently correlated to vertebral BMD changes during teriparatide treatment. CONCLUSION: A minority of treated women had no vertebral densitometric gain after 18 months of teriparatide therapy. Low levels of baseline bone remodeling were the main factor associated with poor response to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Menopause Center, Paule de Viguier Hospital, 330 Avenue de Grande-Bretagne, TSA 70034, Toulouse Cedex 9, 31059, Toulouse, France. gosset.a@chu-toulouse.fr.
- Menopause Center, Paule de Viguier Hospital, 330 Avenue de Grande-Bretagne, TSA 70034, Toulouse Cedex 9, 31059, Toulouse, France.
Zitieren
APA
Anna, G., Anne-Lise, F., Clémence, D., Jean-Michel, P., & Florence, T. (2023). Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis. Journal of Bone and Mineral Metabolism. https://doi.org/10.1007/s00774-023-01412-3
Vancouver
Anna G, Anne-Lise F, Clémence D, Jean-Michel P, Florence T. Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis. Journal of Bone and Mineral Metabolism. 2023. doi:10.1007/s00774-023-01412-3
BibTeX
@article{Anna2023,
author = {Anna, Gosset and Anne-Lise, Farcy and Clémence, Dufond and Jean-Michel, Pouillès and Florence, Trémollieres},
title = {Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis},
journal = {Journal of Bone and Mineral Metabolism},
year = {2023},
doi = {10.1007/s00774-023-01412-3}
}
EUVIMED